Two oral drugs for KRAS G12C solid tumors
Part of Cancer clinical trials.
This trial tests two pills together (GH21 and D-1553) for people whose cancer has a specific genetic marker called KRAS G12C. The goal is to see if this combination can shrink tumors or slow cancer growth, especially after other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a specific genetic change called KRAS G12C in your tumor.
- You have already tried standard treatments (or they are not available for you), and you have also been treated with a KRAS G12C inhibitor before.
- You have at least one tumor that can be measured on scans.
- You are in reasonably good health overall (able to care for yourself and up and about more than half the day).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new combination of two study drugs (GH55 and GH21) for people with advanced solid tumors that have certain genetic changes. The goal is to see if the combo is safe and can help shrink tumors or slow their growth.
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
This study tests a new combination of two oral drugs (GH21 and D-1553) for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to see if the combination is safe and effective in shrinking or controlling the cancer.
This trial tests two new drugs together for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The treatment may help shrink tumors or slow their growth.
This trial tests a new oral pill called HS-10529 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or slow their growth, and to check its safety.
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.